billHR580•Event Tuesday, January 13, 2026Analyzed

Unfunded Mandates Accountability and Transparency Act of 2025

Neutral

Summary

HR580 is a procedural bill amending the Unfunded Mandates Reform Act of 1995 to require regulatory impact analyses for 'major rules'. It does not authorize or appropriate any spending, nor does it create direct revenue or cost obligations for any publicly traded company. The bill has been reported out of committee but awaits floor action.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR580 is a regulatory process bill with zero direct funding or mandate in dollar terms.
2.No public company is directly financially impacted by this legislation as written.
3.The bill is moderately active but only partially through the legislative process (committee report to floor).

Market Implications

No immediate market implications. The bill does not create or redirect any funding and imposes no direct compliance costs on publicly traded companies. If enacted, the main effect would be to increase transparency and potentially slow the pace of major rulemaking — this could provide minor, distant benefits to regulated industries by raising the bar for new costly rules, but the effect is too remote and uncertain to support any specific investment thesis today.

Full Analysis

HR580 was introduced on January 21, 2025 by Rep. Foxx (R-NC5) and reported (amended) by the Committee on Oversight and Government Reform on January 13, 2026. It is now on the Union Calendar (Calendar No. 381) awaiting House floor consideration. The bill amends the Unfunded Mandates Reform Act of 1995 by adding definitions and requirements for regulatory impact analyses on 'major rules' — rules with an annual economic effect >$100M, major cost increases, or significant adverse effects on competition, employment, etc. No appropriation or authorization of funds is involved. The bill is purely procedural, focused on internal regulatory review processes within the executive branch. As a result, there are no direct revenue implications for specific publicly traded companies. The bill's progress is moderate but not accelerated; 17 actions total, with the last significant action being a 23-19 committee vote. The companion bill S4151 is in the Senate. Until the bill reaches the floor and passes, any potential indirect effects on regulatory costs for industries remain speculative and distant.